As the half-lives of commonly used PD-1/PD-L1 inhibitors in advanced NSCLC patients range between 3 and 4 weeks, elucidating the safety of RT around the timing of ICI will also help clinical decision making to proceed or delay RT during the period [15]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.